Skip to main content

Plexiform Neurofibroma clinical trials at UC Health

2 research studies open to eligible people

Showing trials for
  • Experimental MEK Inhibitor Mirdametinib (PD-0325901) for Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

    open to eligible people ages 2 years and up

    This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901).

    at UC Davis UCLA

  • Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

    open to eligible people ages 1 year and up

    This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib. The primary objective is to determine if there is an adequate level of disease responsiveness to binimetinib in children and adults with NF1 and inoperable plexiform neurofibromas. The objective response to binimetinib is defined as ≥ 20% decrease in tumor volume reduction by 12 courses.


Last updated: